

**Corona-Solution Online-Konferenz  
WHO – Diktatur zu Deinem Besten  
26.05.2023**

***Prof. Dr. Klaus Steger***

**Frage 1**

**Beruhen die Empfehlungen der WHO auf wissenschaftlicher Evidenz? Eine Analyse am Beispiel des PCR-Tests.**

**Frage 2**

**Viele konventionelle Impfstoffe sollen laut WHO auf RNA-Technologie umgestellt werden. Welche Chancen/Gefahren bergen die von EU/WHO propagierten RNA-basierten „Impfungen?“**

# WHO – recommendations...

... in regard with COVID-19 were intransparent and pseudo-scientific

Exemplarily shown for the RT-PCR test  
for the detection of SARS-CoV-2

Details & References 

International Journal of Vaccine Theory, Practice, and Research

**IJVTPR**

*RT-PCR Test Targeting the Conserved 5'-UTR  
of SARS-CoV-2 Overcomes Shortcomings of the First  
WHO-Recommended RT-PCR Test*

Ulrike Kämmerer, PhD<sup>1</sup>, Sona Pekova, PhD<sup>2</sup>, Rainer J. Klement, PhD<sup>3</sup>,  
Rogier Louwen, PhD<sup>4</sup>, Pieter Borger, PhD<sup>5</sup>, Klaus Steger, PhD<sup>6</sup>



WHO Director General  
Tedros Adhanom Ghebreyesus:  
“We have a simple message to  
all countries - *test, test, test.*”

**16. March 2020**

According to ourworldindata.com

13.982 PCR-positive “cases” worldwide

871 deaths (“of” or “with”) worldwide

WHO definition of pandemic influenza, changed in 2009:

**An influenza pandemic occurs when a new influenza virus appears against which the human population has no immunity, resulting in several simultaneous epidemics ~~worldwide with enormous numbers of deaths and illness.~~**

For details, refer to: Doshi P (2011) The elusive definition of pandemic influenza. Bulletin WHO 89:532-538.

<https://www.aerzteblatt.de/nachrichten/115217/T-Zellen-gegen-saisonale-Coronaviren-erkennen-auch-SARS-CoV-2>

Ärzteblatt (31.07.2020): **T-Zellen gegen saisonale Coronaviren erkennen auch SARS-CoV-2**

<https://doi.org/10.21203/rs.3.rs-35331/v1>

**SARS-CoV-2 T-cell epitopes define heterologous and COVID-19-induced T-cell recognition**

Immunity = MORE THAN antibodies!

Infection = Update (Cross-immunity)

New is NOT highly infectious is NOT highly mortal

**30.12.2019**

Wuhan Hospital reports 7 patients with severe pneumonia of unknown origin  
➡ **0.000002%** of the 11-million-city of Wuhan

**09.01.2020**

Chinese Center of Disease Control (CCDC) informed the WHO on  
➡ virus sequence and RT-PCR protocol

**13.01.2020**

The WHO publishes the first RT-PCR protocol on the WHO-webpage  
➡ NOT the CCDC-protocol, BUT the Charité-protocol



**21.01.2020**

Submission to Eurosurveillance



**23.01.2020**

Publication in Eurosurveillance

**25 deaths worldwide**

- **Authors used sequence deposited in GISAID database by the CCDC for primer design - NO patient samples and NO virus material was available to validate the test.**
- **No identification of a Ct-value and a cut-off window to discriminate between potentially infectious and certainly not infectious individuals.**
- **Recommendation of 45 PCR cycles** → Have NOT been corrected – even after it was known that the infectious viral load correlates with Ct 30 and later Ct 25.

## Where is the evidence for changing the test strategy?

### WHO-recommendation from 13.01.2020

Testing of 100.000 healthy individuals with 3 genes (E, RdRp, N) will result in  $100.000 \times (0.0269 \times 0.0577 \times 0.0692)$

= **10** false-positive results

### WHO-recommendation from 17.01.2020

Testing of 100.000 healthy individuals with 2 genes (E, RdRp) will result in  $100.000 \times (0.0269 \times 0.0577)$

= **155** false-positive results

### WHO-recommendation from 02.03.2020

Testing of 100.000 healthy individuals with 1 gene (E) will result in  $100.000 \times 0.0269$

= **2690** false-positive results

Target gene	No. of tests performed with different test kits	Specificity-Test 1 Cell culture (virus-free) Correctly identified as negative Cases [%]	Specificity-Test 2 Cell culture (with HCoV229E*) Correctly identified as SARS-CoV-2 negative Cases [%]	Mean specificity from samples 1 and 2 [%]	Mean error rate (false-positives) (100 – mean specificity) [%]
E-gene	373	371 [99.46]	355 [95.17]	97.31	2.69
RdRp-gene	182	178 [97.80]	165 [90.66]	94.23	5.77
N-gene	166	164 [98.20]	146 [87.95]	93.08	6.92

Ringversuch 340 Virusgenom Nachweis SARS CoV 2

**Kary Mullis**  
established PCR in 1983 and was  
awarded the Nobel Prize in 1993:

**EVERYTHING WAS KNOWN  
FROM THE BEGINNING**

# Where is the evidence for asymptomatic testing?

## WHO Information Notice for Users 2020/05

### Nucleic acid testing (NAT) technologies that use polymerase chain reaction (PCR) for detection of SARS-CoV-2


20 January 2021 | Medical product alert | Geneva | Reading time: 1 min (370 words)

WHO guidance [Diagnostic testing for SARS-CoV-2](#) states that careful interpretation of weak positive results is needed (1). The cycle threshold (Ct) needed to detect virus is inversely proportional to the patient's viral load. Where test results do not correspond with the clinical presentation, a new specimen should be taken and retested using the same or different NAT technology.

WHO reminds IVD users that disease prevalence alters the predictive value of test results; as disease prevalence decreases, the risk of false positive increases (2). This means that the probability that a person who has a positive result (SARS-CoV-2 detected) is truly infected with SARS-CoV-2 decreases as prevalence decreases, irrespective of the claimed specificity.

Most PCR assays are indicated as an aid for diagnosis, therefore, health care providers must consider any result in combination with timing of sampling, specimen type, assay specifics, clinical observations, patient history, confirmed status of any contacts, and epidemiological information.

Watson J, Whiting PF, Brush JE (2020) Interpreting a covid-19 test result. BMJ 369:m1808.



- The Ct-value is inversely proportional to the viral load:
- Weak positive test results [= high Ct-values] need careful interpretation.
- **BUT:** Still no recommendation of any cut-off window!



Decreasing prevalence increases the risk for false-positive test result – independent from specificity and sensitivity!



PCR can only support, but not replace medical differential diagnosis!

# RNA-based „vaccine“ technology

*“Gene Therapy Products (GTPs) are all products that mediate their effects by transcription and/or translation of transferred genetic material and/or by integrating into the host genome and that are administered as nucleic acids, viruses, or genetically engineered microorganisms.” (FDA).*


Already in 2005, the WHO excluded nucleic acid-based injections against infections from GTPs and grant them the status of a vaccine: *“Antigens produced in vivo in the vaccinated host following administration of a live vector or nucleic acid or antigens produced by chemical synthesis in vitro.”* (WHO guidelines on non-clinical evaluation of vaccines, Annex 1, TRS No 927, 1 January 2005).

**RNA-based products for a small proportion of the human population, i.e., cancer patients, require strict controls..., but  
RNA-based products – to prevent an (even mild) infection - for the majority of the human population in good health require NO strict controls... !?!**

# RNA-based injections cause harm on at least 5 levels

## The Trojan Horse

Lipid Nanoparticles (LNPs) mimic exosomes, which pass biological barriers and smuggle modRNA in cells → contain allergic polyethylene glycol and toxic cationic lipids (→ ROS → DNA fragmentation, apoptosis)



## The devil in disguise

Modified RNA (modRNA) mimics messenger RNA (mRNA), but forces healthy cells to synthesize a foreign viral protein → contain methyl-pseudouridine → longevity → maximal translational efficiency

## The “red cloth”

Omnipresence of foreign antigen in body results in hyper-inflammation

## The “kill-me” signal

Foreign antigen presented at cell surface transforms cell from friend to foe


**Worst Case Scenario:** Genome integration of modRNA / contaminating DNA

→ Dysregulated gene expression, mutations (i.e., cancer), heritability (germ cells)

RNA: <https://doi.org/10.3390/cimb44030073>

DNA: <https://kevinmckernan.substack.com/>

<https://doctors4covidethics.org/alternate-mechanisms-of-mrna-vaccine-toxicity-which-one-is-the-main-culprit/> by Michael Palmer




## mRNA

- Lifetime: Minutes/Hours
- Cell-specific




Adaptation of cell metabolism to changing living conditions




## modRNA

- Lifetime: Weeks/Months
- Ubiquitous



There is NO rationale at all why any cell of our body should produce as many molecules of a foreign viral protein as possible for as long as possible - which in addition transforms this cell into a target to be attacked by our immune system.

# Perspective: Self-amplifying RNA



**An Update on Self-Amplifying mRNA Vaccine Development**

by Anna K. Blakney <sup>1,\*</sup> , Shell Ip <sup>2</sup> and Andrew J. Geall <sup>2</sup>